MSH Capital Advisors LLC Takes $418,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

MSH Capital Advisors LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,125 shares of the medical research company's stock, valued at approximately $418,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter worth approximately $33,000. Lee Danner & Bass Inc. purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. grew its position in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after acquiring an additional 85 shares in the last quarter. Versant Capital Management Inc grew its holdings in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA during the fourth quarter valued at $60,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. UBS Group cut their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Truist Financial cut their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Finally, JPMorgan Chase & Co. cut their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Six analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $241.50.

IQVIA Stock Up 1.2 %

Shares of NYSE IQV traded up $1.75 during midday trading on Tuesday, hitting $142.97. The company's stock had a trading volume of 495,296 shares, compared to its average volume of 1,679,805. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $25.21 billion, a price-to-earnings ratio of 19.07, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88. The business's fifty day simple moving average is $175.30 and its two-hundred day simple moving average is $195.79.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.